Clinical study with cancer vaccine combined with Anti-PD1 (Pembrolizumab) in malignant lymphoma

Mise à jour : Il y a 4 ans
Référence : EUCTR2015-003169-28

Femme et Homme

  • | Pays :
  • -
  • | Organes :
  • -
  • | Spécialités :
  • -

Extrait

The main objectives of the trial is to induce systemic immune responses against the lymphoma and correlated clinical responses, and additionally study feasibility and safety


Critère d'inclusion

  • Follicular non-Hodgkin`s lymphoma stage III/IV, untreated or relapsed

Liens